Relaxin-2, a peptide hormone, has demonstrated the ability to restore range of motion and eliminate capsular fibrosis in mouse models of shoulder arthrofibrosis, making it perhaps the most specifically relevant peptide for this condition
The 2 mg starting point from the phase 2 trial was specifically designed for this scenario, since the trial participants included people with varying levels of prior medication exposure
Klinic removes barriers to accessing these treatments by verifying insurance benefits and handling prior authorizations, ensuring a smooth, accessible path to health improvements
is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis
0.63%), as well as a significantly higher risk for aspiration pneumonia (HR = 1.33
They also improve blood circulation to the affected areas, which delivers more nutrients and oxygen to help healing
